Side-by-side · Research reference

DermorphinvsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

Dermorphin

Teriparatide

Primary target

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

N/A — exogenous opioid agonist

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

Site-directed antibodies produced for detection and purificationCucumel 1996

—

02Dosage Protocols

Parameter

Dermorphin

Teriparatide

Legal status

Controlled substance in many jurisdictions · Research only

Not approved for human use.

—

Animal research (ICV)

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

—

Detection limit (doping)

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

—

Duration of action

10–120 minutes (dose-dependent, intrathecal)

—

Evidence basis

Animal studies · In vitro assays

RCT / FDA-approved

Human toxicity

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

—

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Frequency

—

Once daily

Intermittent administration preserves anabolic effect.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Route

—

Subcutaneous (thigh or abdomen)

Timing

—

Morning or evening (flexible)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

Dermorphin

Teriparatide

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

Dermorphin

Teriparatide

Opioid effects

Respiratory depression, sedation, euphoria, tolerance, dependence risk

—

CNS effects

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

—

Kambô ritual toxicity

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

—

Peripheral effects

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

—

Receptor selectivity caveat

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

—

Proteolytic stability

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

Dermorphin

Teriparatide

1. Legal and ethical framework

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Animal research protocols

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Analytical detection

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Kambô ritual (traditional use)

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Monitoring

—

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.